Literature DB >> 33216886

SF3B1-mutant CMML defines a predominantly dysplastic CMML subtype with a superior acute leukemia-free survival.

Kitsada Wudhikarn1,2, Sanam Loghavi3, Abhishek A Mangaonkar1, Aref Al-Kali1, Moritz Binder1, Ryan Carr1, Kaaren Reichard4, Christy Finke1, Matthew Howard4, Naseema Gangat1, Ayalew Tefferi1, Rami Komrokji5, Najla Ali4, Terra Lasho1, Rhett Ketterling4, Eric Padron4, Mrinal M Patnaik1.   

Abstract

Entities:  

Year:  2020        PMID： 33216886      PMCID： PMC7686903          DOI： 10.1182/bloodadvances.2020003345

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  9 in total

1.  Revised international prognostic scoring system for myelodysplastic syndromes.

Authors:  Peter L Greenberg; Heinz Tuechler; Julie Schanz; Guillermo Sanz; Guillermo Garcia-Manero; Francesc Solé; John M Bennett; David Bowen; Pierre Fenaux; Francois Dreyfus; Hagop Kantarjian; Andrea Kuendgen; Alessandro Levis; Luca Malcovati; Mario Cazzola; Jaroslav Cermak; Christa Fonatsch; Michelle M Le Beau; Marilyn L Slovak; Otto Krieger; Michael Luebbert; Jaroslaw Maciejewski; Silvia M M Magalhaes; Yasushi Miyazaki; Michael Pfeilstöcker; Mikkael Sekeres; Wolfgang R Sperr; Reinhard Stauder; Sudhir Tauro; Peter Valent; Teresa Vallespi; Arjan A van de Loosdrecht; Ulrich Germing; Detlef Haase
Journal:  Blood       Date:  2012-06-27       Impact factor: 22.113

2.  Frequent pathway mutations of splicing machinery in myelodysplasia.

Authors:  Kenichi Yoshida; Masashi Sanada; Yuichi Shiraishi; Daniel Nowak; Yasunobu Nagata; Ryo Yamamoto; Yusuke Sato; Aiko Sato-Otsubo; Ayana Kon; Masao Nagasaki; George Chalkidis; Yutaka Suzuki; Masashi Shiosaka; Ryoichiro Kawahata; Tomoyuki Yamaguchi; Makoto Otsu; Naoshi Obara; Mamiko Sakata-Yanagimoto; Ken Ishiyama; Hiraku Mori; Florian Nolte; Wolf-Karsten Hofmann; Shuichi Miyawaki; Sumio Sugano; Claudia Haferlach; H Phillip Koeffler; Lee-Yung Shih; Torsten Haferlach; Shigeru Chiba; Hiromitsu Nakauchi; Satoru Miyano; Seishi Ogawa
Journal:  Nature       Date:  2011-09-11       Impact factor: 49.962

3.  Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance.

Authors:  Mrinal M Patnaik; Terra L Lasho; Christy M Finke; Curtis A Hanson; Janice M Hodnefield; Ryan A Knudson; Rhett P Ketterling; Animesh Pardanani; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2013-01-18       Impact factor: 10.047

Review 4.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors:  Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

5.  Prognostic score including gene mutations in chronic myelomonocytic leukemia.

Authors:  Raphaël Itzykson; Olivier Kosmider; Aline Renneville; Véronique Gelsi-Boyer; Manja Meggendorfer; Margot Morabito; Céline Berthon; Lionel Adès; Pierre Fenaux; Odile Beyne-Rauzy; Norbert Vey; Thorsten Braun; Torsten Haferlach; François Dreyfus; Nicholas C P Cross; Claude Preudhomme; Olivier A Bernard; Michaela Fontenay; William Vainchenker; Susanne Schnittger; Daniel Birnbaum; Nathalie Droin; Eric Solary
Journal:  J Clin Oncol       Date:  2013-05-20       Impact factor: 44.544

6.  ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients.

Authors:  M M Patnaik; R Itzykson; T L Lasho; O Kosmider; C M Finke; C A Hanson; R A Knudson; R P Ketterling; A Tefferi; E Solary
Journal:  Leukemia       Date:  2014-04-03       Impact factor: 11.528

7.  Single-cell genomics reveals the genetic and molecular bases for escape from mutational epistasis in myeloid neoplasms.

Authors:  Justin Taylor; Xiaoli Mi; Khrystyna North; Moritz Binder; Alexander Penson; Terra Lasho; Katherine Knorr; Michael Haddadin; Bo Liu; Joseph Pangallo; Salima Benbarche; Daniel Wiseman; Ayalew Tefferi; Stephanie Halene; Yang Liang; Mrinal M Patnaik; Robert K Bradley; Omar Abdel-Wahab
Journal:  Blood       Date:  2020-09-24       Impact factor: 25.476

Review 8.  SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS.

Authors:  Luca Malcovati; Kristen Stevenson; Elli Papaemmanuil; Donna Neuberg; Rafael Bejar; Jacqueline Boultwood; David T Bowen; Peter J Campbell; Benjamin L Ebert; Pierre Fenaux; Torsten Haferlach; Michael Heuser; Joop H Jansen; Rami S Komrokji; Jaroslaw P Maciejewski; Matthew J Walter; Michaela Fontenay; Guillermo Garcia-Manero; Timothy A Graubert; Aly Karsan; Manja Meggendorfer; Andrea Pellagatti; David A Sallman; Michael R Savona; Mikkael A Sekeres; David P Steensma; Sudhir Tauro; Felicitas Thol; Paresh Vyas; Arjan A Van de Loosdrecht; Detlef Haase; Heinz Tüchler; Peter L Greenberg; Seishi Ogawa; Eva Hellstrom-Lindberg; Mario Cazzola
Journal:  Blood       Date:  2020-07-09       Impact factor: 25.476

9.  Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients.

Authors:  Giacomo Coltro; Abhishek A Mangaonkar; Terra L Lasho; Christy M Finke; Prateek Pophali; Ryan Carr; Naseema Gangat; Moritz Binder; Animesh Pardanani; Martin Fernandez-Zapico; Keith D Robertson; Alberto Bosi; Nathalie Droin; Alessandro M Vannucchi; Ayalew Tefferi; Anthony Hunter; Eric Padron; Eric Solary; Mrinal M Patnaik
Journal:  Leukemia       Date:  2019-12-13       Impact factor: 11.528
  9 in total
  8 in total

Review 1.  Treatment advances for pediatric and adult onset neoplasms with monocytosis.

Authors:  Kristen B McCullough; Alexis K Kuhn; Mrinal M Patnaik
Journal:  Curr Hematol Malig Rep       Date:  2021-03-16       Impact factor: 3.952

Review 2.  Laboratory Evaluation and Pathological Workup of Neoplastic Monocytosis - Chronic Myelomonocytic Leukemia and Beyond.

Authors:  Siba El Hussein; Joseph D Khoury; L Jeffrey Medeiros; Sanam Loghavi
Journal:  Curr Hematol Malig Rep       Date:  2021-05-04       Impact factor: 3.952

Review 3.  Chronic Myelomonocytic Leukemia: Hematopathology Perspective.

Authors:  Siba El Hussein; Sa A Wang; Naveen Pemmaraju; Joseph D Khoury; Sanam Loghavi
Journal:  J Immunother Precis Oncol       Date:  2021-06-18

Review 4.  Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms.

Authors:  Michael J Hochman; Bipin N Savani; Tania Jain
Journal:  EJHaem       Date:  2021-07-19

5.  How I diagnose and treat chronic myelomonocytic leukemia.

Authors:  Mrinal M Patnaik
Journal:  Haematologica       Date:  2022-07-01       Impact factor: 11.047

Review 6.  Mouse Models of CMML.

Authors:  Ekaterina Belotserkovskaya; Oleg Demidov
Journal:  Int J Mol Sci       Date:  2021-10-26       Impact factor: 5.923

7.  SF3B1-mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity.

Authors:  Abhishek A Mangaonkar; Terra L Lasho; Christy Finke; Rhett P Ketterling; Kaaren K Reichard; Kristen McCullough; Naseema Gangat; Aref Al-Kali; Kebede H Begna; William H Hogan; Mark R Litzow; Hassan Alkhateeb; Mithun Shah; Animesh Pardanani; Ayalew Tefferi; Najla H Al Ali; Chetasi Talati; David Sallman; Eric Padron; Rami Komrokji; Mrinal M Patnaik
Journal:  Haematologica       Date:  2022-05-01       Impact factor: 11.047

Review 8.  SF3B1 Mutations in Hematological Malignancies.

Authors:  Daniela Cilloni; Federico Itri; Valentina Bonuomo; Jessica Petiti
Journal:  Cancers (Basel)       Date:  2022-10-08       Impact factor: 6.575
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.